AI brings savings to clinical trials: study
Summary
A study from the Tufts Center shows that using artificial intelligence (AI) in cancer drug trials can save time and money by speeding up patient recruitment, data monitoring, and analysis. AI tools can reduce late-stage trial costs by millions of dollars and may soon become a normal part of clinical trials.Key Facts
- AI can shorten cancer drug trials by about 10 weeks.
- Using AI can cut operating costs by up to $5.6 million in late-stage clinical trials.
- The study applied AI to a phase 2 and 3 cancer drug trial using Medable’s platform.
- AI helped reduce site visits, speed up patient enrollment, and secure trial data.
- Trials with drugs targeting many tumor types could see benefits up to $565 million.
- AI could become common in clinical trials within three to five years.
- AI tools may help track trial diversity and provide early drug safety and effectiveness data.
- AI does not guarantee trial success and still requires human oversight for some tasks.
Read the Full Article
This is a fact-based summary from The Actual News. Click below to read the complete story directly from the original source.
